Treating erectile dysfunction by endothelial rehabilitation with phosphodiesterase 5 inhibitors

World Journal of Urology

Volumn 23, Issue 6, 2005, Pages 385-392

  Sommer, Frank ^a   Schulze, Wolfgang ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Endothelial function; Endothelial rehabilitation; Erectile dysfunction; PDE5 inhibitors

Indexed keywords

CGMP BINDING, CGMP SPECIFIC 3',5' CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CGMP-BINDING, CGMP-SPECIFIC 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CYCLIC GMP PHOSPHODIESTERASE; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR;

ANIMAL; CARDIOVASCULAR DISEASE; DRUG EFFECT; HUMAN; IMPOTENCE; MALE; PHYSIOLOGY; REVIEW; RISK FACTOR; VASCULAR ENDOTHELIUM;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ANIMALS; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HUMANS; IMPOTENCE; MALE; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; RISK FACTORS;

EID: 31144472113     PISSN: 07244983     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00345-005-0021-7     Document Type: Review

References (31)

1. Verma S, Buchanan MR, Anderson TJ (2003) Endothelial function as a biomarker of vascular disease. Circulation 108:2054-2059 10.1161/ 01.CIR.0000089191.72957.ED
2. Kloner RA, Speakman M (2002) Erectile dysfunction and atherosclerosis. Curr Atheroscler Rep 4:397-401 12162940
3. Soloman H, Man JW, Jackson G (2003) Erectile dysfunction and the cardiovascular patient: Endothelial dysfunction is the common denominator. Heart 89:251-254 10.1136/heart.89.3.251
4. Rosen MP, Greenfield AJ, Walker TG, et al (1991) Cigarette smoking: An independent risk factor for atherosclerosis in the hypogastric-cavernous arterial bed of men with atherogenic impotence. J Urol 145:759-763 2005695
5. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, Mc Kinlay JB (1994) Impotence and its medical and psychological correlates: Results of the Massachusetts Male Aging Study. J Urol 151:54-61 8254833
6. Lue T (2000) Erectile dysfunction. N Engl J Med 342:1802-1813 10.1056/ NEJM200006153422407
7. Sullivan ME, Thompson CS, Dashwood MR, Khan MA, Jeremy JY, Morgan RJ, Mikhailidis DP (1999) Nitric oxide and penile erection: Is erectile dysfunction another manifestation of vascular disease? Cardiovasc Res 43:658-665 10.1016/S0008-6363(99)00135-2
8. Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U (2000) Epidemiology of erectile dysfunction: Results of the 'Cologne Male Survey'. Int J Impot Res 12(6):305-311 10.1038/sj.ijir.3900622
9. Jardin A, Wagner G, Khoury S et al (1999) Recommendations of the 1st International Consultation on Erectile Dysfunction. Co-sponsored by the World Health Organization (WHO), International Consultation on Urological Diseases (ICUD) and Societe Internationale d'Urologie (SIU) and held July 1-3, 1999, Paris, 2000, p 713
10. Aytac IA, McKinlay JB, Krane RJ (1999) The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 84:50-56 10.1046/j.1464-410x.1999.00142.x
11. Montorsi F, Briganti A, Salonia A, et al. (2003) Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol 44:360-365 10.1016/ S0302-2838(03)00305-1
12. I, Saenz Tejada de N, Gonzales Cadavid JP, Heaton et al. (2000) Anatomy, physiology and pathophysiology of erectile dysfunction. In: A, Jardin G, Wagner S, Khoury F, Giuliano H, Padma-Nathan RC Rosen (eds) Erectile dysfunction. Health Publications Ltd., Plymouth, pp 65-102
13. Terradas C, Levalle O, Nagelberg A, Mormandi E (2001) Sildenafil improves nocturnal penile erections in organic impotence. Int J Impot Res 13(2):125-129 10.1038/sj.ijir.3900656
14. Ballard SA, Gingell CJ, Tang K, Turner LA, Price ME, Naylor AM (1998) Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol 159:2164-2171 10.1097/ 00005392-199806000-00142
15. Hellstrom WJ, Gittelman M, Karlin G, Segerson T, Thibonnier M, Taylor T, Padma-Nathan H, Vardenafil Study Group (2003) Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: Results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology 61(4 Suppl. 1):8-14 10.1016/S0090-4295(03)00115-8
16. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker WA, et al (1998) Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 338:1397-1404 10.1056/NEJM199805143382001
17. Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, Watkins V, Anglin G, Whitaker S (2002) Efficacy and safety of tadalafil for the treatment of erectile dysfunction: Results of integrated analyses. J Urol 168(4 Pt 1):1332-1336 10.1097/00005392-200210010-00006
18. Desouza C, Parulkar A, Lumpkin D, Akers D, Fonseca VA (2002) Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Diabetes Care 25(8):1336-1339 12145231
19. Montorsi F, Maga T, Strambi LF, et al (2000) Sildenafil taken at bedtime significantly increases nocturnal erections: Results of a placebo-controlled study. Urology 56(6):906-911 10.1016/ S0090-4295(00)00841-4
20. Rochira V, Granata AR, Balestrieri A, Madeo B, Carani C (2002) Effects of sildenafil on nocturnal penile tumescence and rigidity in normal men: randomized, placebo-controlled, crossover study. J Androl 23(4):566-571 12065465
21. El Galley R, Rutland H, Talic R, Keane T, Clark H (2001) Long-term efficacy of sildenafil and tachyphylaxis effect. J Urol 166:927-931 10.1097/00005392-200109000-00028
22. Behr-Roussel D, Gorny D, Mevel K, Caisey S, Bernabé J, Burgess G, Wayman C, Alexandre L, Giuliano F (2005) Chronic sildenafil improves erectile function and endothelium-dependent cavernosal relaxations in rats: Lack of tachyphylaxis. Eur Urol 47:87-91 10.1016/ j.eururo.2004.09.005
23. Rosano GMC, Aversa A, Vitale C, Fabbri A, Fini M, Spera G (2005) Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 47:214-222 10.1016/ j.eururo.2004.10.002
24. Caretta N, Palego P, Ferlin A, Garolla A, Bettella A, Selice R, Foresta C (2005) Resumption of spontaneous erections in selected patients affected by erectile dysfunction and various degrees of carotid wall alteration: Role of tadalafil. Eur Urol 48:326-332 10.1016/ j.eururo.2005.01.013
25. Porst H. Salvagetherapie mit täglicher Dosierung von Sildenafil bei Non-Respondern auf on demand Therapie mit 100 mg Sildenafil. Presented at the 55th Congress of the German Urological Association, Hamburg, Germany, 24-27 September 2003
26. Porst H, van Ahlen H (1988) Stellenwert nächtlicher peniler Tumeszenz- und Rigiditätsmessungen (NPT) mit dem Rigiscan® bei erektiler Dysfunktion. Aktuel Urol 19:21-25
27. Kim N, Vardi Y, Padma-Nathan H, Daley J, Goldstein I, Saenz de Tejada I (1993) Oxygen tension regulates the nitric oxide pathway. Physiological role in penile erection. J Clin Invest 91(2):437-442 7679408
28. Foresta C, Caretta N, Lana A, Cabrelle A, Palu G, Ferlin A (2005) PDE-5 inhibitor, vardenafil, increases circulating progenitor cells in humans. Int J Impot Res 17(4):377-380 10.1038/sj.ijir.3901325
29. Aicher A, Heeschen C, Dimmeler S (2004) The role of NOS3 in stem cell mobilization. Trends Mol Med 10:421-425 10.1016/j.molmed.2004.07.007
30. Foresta C, Caretta N, Lana A, Cabrelle A, Palu G, Ferlin A (2005) Circulating progenitor cells in subjects with erectile dysfunction. Int J Impot Res 17(3):288-290 10.1038/sj.ijir.3901311
31. Ornish D, Brown SE, Scherwitz LW, et al (1990) Can lifestyle changes reverse coronary heart disease? The lifestyle heart trial. Lancet 336(8708):129-133 10.1016/0140-6736(90)91656-U